Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Pausing certain arthritis drugs after COVID-19 vaccination raises flare risk without improving antibody response (opens in a new tab)

medicalxpress.com · 2026-10-06

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 4 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Pausing certain arthritis drugs after COVID-19 vaccination raises flare risk without improving antibody response

medicalxpress.com · 2026-10-06

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Supported

Every claim holds up. All four claims match what the study reports.

  • 4 supported
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4SupportedHolding select biologic or JAK inhibitor DMARDs for two weeks at the time of a supplemental COVID-19 vaccine dose does not enhance humoral immunogenicity in patients with inflammatory arthritis.View evidenceHide evidence

As statedgeometric mean fold rise ratio (hold/continue) 0.96; 95% CI, 0.36 to 2.56

Why this verdict

The abstract-level profile describes a randomized trial in which patients continued or held select biologic/targeted synthetic DMARDs for 2 weeks after a supplemental mRNA COVID-19 vaccine dose. The primary humoral immunogenicity outcome showed no significant improvement with holding therapy: GMFR ratio hold/continue 0.96, 95% CI 0.36–2.56. The story’s causal framing is appropriate for this randomized comparison.

1

Study evidence

No significant improvement in humoral immunogenicity (anti–SARS-CoV-2 spike IgG GMFR) from holding therapy for 2 weeks after supplemental mRNA vaccination compared with continuing therapy.GMFR ratio (hold/continue) 0.96 (95% CI, 0.36–2.56)

“The COVID-19 Vaccine Response (COVER) trial was a multicenter randomized clinical pragmatic trial”
Claim 2 of 4SupportedDisease flare risk was significantly increased with holding therapy, especially among patients using JAK inhibitor therapies.View evidenceHide evidence

As statedodds ratio, 2.27; 95% CI, 1.41 to 3.65

Why this verdict

The profile reports that holding therapy significantly increased disease flare risk, with OR 2.27 and 95% CI 1.41–3.65, and states that the flare signal was most pronounced among JAK inhibitor users. Because this was a randomized hold-vs-continue comparison, the causal wording is supported at abstract depth, though the profile notes the flare outcome was secondary and subgroup effect estimates are not provided in the abstract.

1

Study evidence

Holding therapy for 2 weeks around a supplemental COVID-19 vaccine dose increased the risk of clinician-ascertained disease flares compared with continuing therapy.Odds ratio 2.27 (95% CI, 1.41–3.65)

“Secondary outcomes included disease flares and vaccine-related adverse events.”
Claim 3 of 4SupportedJeffrey R. Curtis and colleagues randomly assigned 840 patients with inflammatory arthritis to continue or hold therapy for two weeks after their next supplemental COVID-19 vaccine dose.View evidenceHide evidence

As stated840 patients

Why this verdict

The profile reports 840 randomized participants in the COVER pragmatic multicenter randomized trial and states that patients were randomized to continue or hold therapy for 2 weeks following their next COVID-19 supplemental dose. The supplied profile does not separately list author metadata, but the scientific/design content of the claim is supported.

1

Study evidence

No significant improvement in humoral immunogenicity (anti–SARS-CoV-2 spike IgG GMFR) from holding therapy for 2 weeks after supplemental mRNA vaccination compared with continuing therapy.GMFR ratio (hold/continue) 0.96 (95% CI, 0.36–2.56)

“The COVID-19 Vaccine Response (COVER) trial was a multicenter randomized clinical pragmatic trial”
Claim 4 of 4SupportedThe authors conclude that these findings do not support routine temporary interruption of these drugs for COVID-19 vaccine optimization.View evidenceHide evidence

Why this verdict

The profile states that the authors concluded routine interruption of these therapies around supplemental COVID-19 vaccination is likely not warranted, based on no humoral immunogenicity benefit and increased flare risk. The story’s quoted conclusion closely matches the paper profile.

1

Study evidence

No significant improvement in humoral immunogenicity (anti–SARS-CoV-2 spike IgG GMFR) from holding therapy for 2 weeks after supplemental mRNA vaccination compared with continuing therapy.GMFR ratio (hold/continue) 0.96 (95% CI, 0.36–2.56)

“The COVID-19 Vaccine Response (COVER) trial was a multicenter randomized clinical pragmatic trial”
2

Study evidence

Holding therapy for 2 weeks around a supplemental COVID-19 vaccine dose increased the risk of clinician-ascertained disease flares compared with continuing therapy.Odds ratio 2.27 (95% CI, 1.41–3.65)

“Secondary outcomes included disease flares and vaccine-related adverse events.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Important flare caveat: flares were transient, with full recovery in both arms by the 6-week follow-up.

    The story emphasizes increased flare risk but does not mention the abstract-level qualification that flares resolved by 6 weeks, which affects interpretation of clinical harm.

    From Pragmatic randomized clinical trial (hold vs continue DMARD for 2 weeks)

  • Flare outcomes were secondary outcomes, and the abstract does not provide detailed flare definitions, clinician adjudication details, or subgroup confidence intervals for the JAK inhibitor signal.

    The story does not note that flare analyses were secondary or that abstract-level detail is limited for flare ascertainment and subgroup estimates.

    From Pragmatic randomized clinical trial (hold vs continue DMARD for 2 weeks)

  • Adverse event reporting limitation: the abstract does not provide absolute adverse-event counts, severity grading, timing, relatedness details, confidence intervals, or p-values.

    The story mentions adverse events but does not communicate the abstract-level limitation that safety reporting lacks numerical and severity detail.

    From Pragmatic randomized trial (hold vs continue DMARD for 2 weeks)

  • Immunogenicity scope limitation: the primary outcome was anti-spike IgG change, and the abstract does not report neutralizing antibody activity, cellular immunity, assay thresholds, or clinical infection outcomes.

    The story appropriately frames the result as humoral/antibody response, but it does not mention that the abstract-level evidence is limited to anti-spike IgG and does not establish effects on broader immune protection or clinical COVID-19 outcomes.

    From Pragmatic randomized clinical trial

5 things the story did carry across
  • Trial design and intervention: a multicenter pragmatic randomized clinical trial assigning patients with inflammatory arthritis on select biologic or targeted synthetic DMARDs to continue therapy or hold it for 2 weeks after a supplemental mRNA COVID-19 vaccine dose.
  • Primary immunogenicity finding: holding therapy did not significantly improve anti–SARS-CoV-2 spike IgG geometric mean fold rise at 6 weeks compared with continuing therapy.
  • Disease flare finding: holding therapy increased flare risk, with OR 2.27, 95% CI 1.41–3.65, and the signal was most pronounced among JAK inhibitor users.
  • Subgroup consistency for immunogenicity: results were consistent across drug subgroups and drug half-life categories.
  • Adverse event result: vaccine-related adverse events were comparable between arms but were reported more frequently in the hold group.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether temporarily holding select biologic or targeted synthetic DMARDs (anti-TNF, anti–IL-17, abatacept, JAK inhibitors) for 2 weeks after a COVID-19 supplemental mRNA vaccine dose improves humoral immunogenicity compared with continuing therapy.Pragmatic randomized clinical trialExpand

In plain English

COVER was a multicenter pragmatic randomized clinical trial in patients with inflammatory arthritis on stable biologic or targeted synthetic DMARDs (anti–TNF, anti–IL-17, abatacept, JAK inhibitors) who received a supplemental mRNA COVID-19 vaccine dose. Participants were randomized to continue therapy or hold therapy for 2 weeks after vaccination. The prespecified primary outcome was change in anti–SARS-CoV-2 spike IgG from baseline to 6 weeks (GMFR) analyzed by ITT with multiple imputation; a per-protocol sensitivity analysis and subgroup analyses by drug class/half-life were also performed. The trial found no significant difference in humoral immunogenicity between arms (GMFR ratio hold/continue 0.96, 95% CI 0.36–2.56). Holding therapy increased risk of disease flare (OR 2.27, 95% CI 1.41–3.65) with corroborating RA flare questionnaire results (≥10-point worsening: 21.1% vs 9.1%; risk difference 12.0%, 95% CI 5.9%–18.1%); flares were transient with full recovery by 6 weeks. Adverse events were comparable between groups but reported more frequently in the hold group. The authors conclude routine interruption of these therapies around supplemental COVID-19 vaccination is likely not warranted.

Key findings

  • No significant improvement in humoral immunogenicity (anti–SARS-CoV-2 spike IgG GMFR) from holding therapy for 2 weeks after supplemental mRNA vaccination compared with continuing therapy.GMFR ratio (hold/continue) 0.96 (95% CI, 0.36–2.56)
  • Temporarily holding therapy increased risk of disease flare compared with continuing therapy.Odds ratio 2.27 (95% CI, 1.41–3.65)
“The COVID-19 Vaccine Response (COVER) trial was a multicenter randomized clinical pragmatic trial”
What this piece can’t prove
  • Abstract does not report assay-specific details (e.g., assay platform, lower limit, neutralizing activity) or exact serologic thresholds.

4 further details could not be confirmed from the summary.

2human in vivoAssess whether temporarily holding these DMARDs around supplemental COVID-19 vaccination worsens inflammatory arthritis disease activity (flares) compared with continuing therapy.Pragmatic randomized clinical trial (hold vs continue DMARD for 2 weeks)Expand

In plain English

In a multicenter pragmatic randomized trial of patients with inflammatory arthritis receiving biologic or JAK inhibitor therapy, temporary interruption of therapy for 2 weeks around a supplemental COVID-19 vaccine dose increased the risk of disease flares compared with continuing therapy; flares were transient with full recovery by 6-week follow-up. The increased flare signal was most pronounced among JAK inhibitor users and was corroborated by a patient-reported RA Flare Questionnaire.

Key findings

  • Holding therapy for 2 weeks around a supplemental COVID-19 vaccine dose increased the risk of clinician-ascertained disease flares compared with continuing therapy.Odds ratio 2.27 (95% CI, 1.41–3.65)
  • Patient-reported disease worsening on the RA Flare Questionnaire corroborated the increased flare signal in the hold arm.21.1% (54/256) vs 9.1% (23/253) with ≥10-point worsening; risk difference 12.0% (95% CI, 5.9%–18.1%)
“Secondary outcomes included disease flares and vaccine-related adverse events.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3human in vivoCompare vaccine-related adverse events between medication-holding vs continuation strategies around the supplemental COVID-19 vaccine dose.Pragmatic randomized trial (hold vs continue DMARD for 2 weeks)Expand

In plain English

In the COVER pragmatic randomized trial of patients with inflammatory arthritis receiving biologic or JAK inhibitor therapy, vaccine-related adverse events were collected as a prespecified secondary outcome and reported to be comparable between the randomized arms but more frequent in the group that held therapy for 2 weeks around a supplemental COVID-19 vaccine dose.

Key findings

  • Vaccine-related adverse events, collected as a secondary outcome, were reported as comparable between randomized arms but were more frequent in the group that held DMARD therapy for 2 weeks.
“Secondary outcomes included disease flares and vaccine-related adverse events.”
What this piece can’t prove
  • Safety comparisons are secondary analyses; the trial was designed and powered primarily for immunogenicity outcomes (primary endpoint).

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy

Inflammatory Bowel Diseases · 2016 · Crossref

Source (opens in a new tab)
Candidate

Faculty Opinions recommendation of Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine--a randomized trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2017 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.